These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 31696413)

  • 1. Tumor-infiltrating and circulating granulocytic myeloid-derived suppressor cells correlate with disease activity and adverse clinical outcomes in mycosis fungoides.
    Argyropoulos KV; Pulitzer M; Perez S; Korkolopoulou P; Angelopoulou M; Baxevanis C; Palomba ML; Siakantaris M
    Clin Transl Oncol; 2020 Jul; 22(7):1059-1066. PubMed ID: 31696413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples.
    Kotsakis A; Harasymczuk M; Schilling B; Georgoulias V; Argiris A; Whiteside TL
    J Immunol Methods; 2012 Jul; 381(1-2):14-22. PubMed ID: 22522114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased Levels of Circulating Monocytic- and Early-Stage Myeloid-Derived Suppressor Cells (MDSC) in Acute Myeloid Leukemia.
    Lv J; Zhao Y; Zong H; Ma G; Wei X; Zhao Y
    Clin Lab; 2021 Mar; 67(3):. PubMed ID: 33739029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD14
    Bernsmeier C; Triantafyllou E; Brenig R; Lebosse FJ; Singanayagam A; Patel VC; Pop OT; Khamri W; Nathwani R; Tidswell R; Weston CJ; Adams DH; Thursz MR; Wendon JA; Antoniades CG
    Gut; 2018 Jun; 67(6):1155-1167. PubMed ID: 28592438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets.
    Lang S; Bruderek K; Kaspar C; Höing B; Kanaan O; Dominas N; Hussain T; Droege F; Eyth C; Hadaschik B; Brandau S
    Clin Cancer Res; 2018 Oct; 24(19):4834-4844. PubMed ID: 29914893
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunosuppressive effects and mechanisms of three myeloid-derived suppressor cells subsets including monocytic-myeloid-derived suppressor cells, granulocytic-myeloid-derived suppressor cells, and immature-myeloid-derived suppressor cells.
    Nagatani Y; Funakoshi Y; Suto H; Imamura Y; Toyoda M; Kiyota N; Yamashita K; Minami H
    J Cancer Res Ther; 2021; 17(4):1093-1100. PubMed ID: 34528569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous squamous cell carcinomas with markers of increased metastatic risk are associated with elevated numbers of neutrophils and/or granulocytic myeloid derived suppressor cells.
    Seddon A; Hock B; Miller A; Frei L; Pearson J; McKenzie J; Simcock J; Currie M
    J Dermatol Sci; 2016 Aug; 83(2):124-30. PubMed ID: 27160951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive role of CD11b
    Hyun SY; Na EJ; Jang JE; Chung H; Kim SJ; Kim JS; Kong JH; Shim KY; Lee JI; Min YH; Cheong JW
    Cancer Med; 2020 Oct; 9(19):7007-7017. PubMed ID: 32780544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Immune Checkpoint Blockade on Myeloid-Derived Suppressor Cell Populations in Patients With Melanoma.
    Sun SH; Benner B; Savardekar H; Lapurga G; Good L; Abood D; Nagle E; Duggan M; Stiff A; DiVincenzo MJ; Suarez-Kelly LP; Campbell A; Yu L; Wesolowski R; Howard H; Shah H; Kendra K; Carson WE
    Front Immunol; 2021; 12():740890. PubMed ID: 34712230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer - Exploratory Analysis of Their Biomarker Potential.
    Fědorová L; Pilátová K; Selingerová I; Bencsiková B; Budinská E; Zwinsová B; Brychtová V; Langrová M; Šefr R; Valík D; Zdražilová Dubská L
    Klin Onkol; 2018; 31(Suppl 2):88-92. PubMed ID: 31023030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells.
    Azzaoui I; Uhel F; Rossille D; Pangault C; Dulong J; Le Priol J; Lamy T; Houot R; Le Gouill S; Cartron G; Godmer P; Bouabdallah K; Milpied N; Damaj G; Tarte K; Fest T; Roussel M
    Blood; 2016 Aug; 128(8):1081-92. PubMed ID: 27338100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a whole blood assay for quantifying myeloid-derived suppressor cells.
    Apodaca MC; Wright AE; Riggins AM; Harris WP; Yeung RS; Yu L; Morishima C
    J Immunother Cancer; 2019 Aug; 7(1):230. PubMed ID: 31462270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Various skin manifestations of mycosis fungoides: histopathological features and prognosis.
    Koga M; Imafuku S; Nakayama J
    Fukuoka Igaku Zasshi; 2011 Jul; 102(7):229-36. PubMed ID: 21879593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease.
    Pileri A; Agostinelli C; Sessa M; Quaglino P; Santucci M; Tomasini C; Grandi V; Fava P; Astrua C; Righi S; Patrizi A; Pileri SA; Pimpinelli N
    Virchows Arch; 2017 May; 470(5):575-582. PubMed ID: 28321511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients.
    Li J; Srivastava RM; Ettyreddy A; Ferris RL
    J Immunother Cancer; 2015; 3():54. PubMed ID: 26579227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome.
    Geskin LJ; Akilov OE; Kwon S; Schowalter M; Watkins S; Whiteside TL; Butterfield LH; Falo LD
    Cancer Immunol Immunother; 2018 Mar; 67(3):423-434. PubMed ID: 29204699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The study of CD14+HLA-DR-/low myeloid-drived suppressor cell (MDSC) in peripheral blood of peripheral T-cell lymphoma patients and its biological function.
    Du J; Sun X; Song Y
    Cell Mol Biol (Noisy-le-grand); 2017 Mar; 63(3):62-67. PubMed ID: 28466815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
    Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
    Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
    Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
    Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.